OVID
Ovid Therapeutics Inc.
Biotechnology · Healthcare · United States
2.54
close · 2026-10-30
value
40
cheaper than peers40
quality
28
stronger fundamentals28
ranked against
Biotechnology (commercial)
value
quality
162 peerswide variation
Value inputs
| measure | company | vs peers |
| price to book | 2.24× | 67 |
| earnings yield, latest year | -9.1% | 56 |
| cash flow yield, latest year | -7.7% | 55 |
| earnings yield, 1 year ago | -14.6% | 52 |
| cash flow yield, 2 years ago | -9.3% | 48 |
| cash flow yield, 1 year ago | -11.3% | 47 |
| cash flow yield, 3 years ago | -11.4% | 41 |
| earnings yield, 2 years ago | -28.7% | 40 |
| earnings yield, 3 years ago | -30.3% | 38 |
| price to sales | 313.36× | 8 |
10 of 12 measures available
Quality inputs
| measure | company | vs peers |
| debt to equity | 6.1% | 70 |
| return on equity | -26.0% | 69 |
| operating margin | -2100.7% | 12 |
| revenue growth | -88.3% | 6 |
4 of 4 measures available
Facts
| market cap | $496M |
| free cash flow | -$33.1M |
| employees | 23 |
| first trade | 2017-05-05 |
| next earnings | 2026-08-13 |
| fundamentals updated | 2026-08-28 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -0.23 | -0.37 | -0.73 | -0.77 |
| free cash flow | -$38.3M | -$56.1M | -$45.9M | -$56.6M |
| net income | -$17.4M | -$26.4M | -$52.3M | -$54.2M |
| revenue | $7.3M | $566,000 | $392,000 | $1.5M |
| unusual items | not reported | $3.3M | $2.0M | not reported |